Virtus LifeSci Biotech Clinical Trials ETF – AMEX:BBC

Add to watchlist

$22.51

-1.81

-7.48%

Market closed

Open in 2 days

-14.51%

month

-14.51%

quarter

-1.93%

year

Market Cap	10.92M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	N/A

Revenue	N/A
EBITDA	N/A
Income	N/A
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Virtus LifeSci Biotech Clinical Trials ETF
Latest News

Friday, 8 November 2024
11:29	AMC Networks Paying $42M For Full Control Of BBC America	deadline.com
Monday, 7 October 2024
07:02	Amazon Fire TVs to carry Freely streaming platform in boost for BBC and ITV	reuters.com
Tuesday, 23 July 2024
10:44	BBC licence fee income is down 30% since Netflix's UK launch	proactiveinvestors.co.uk
Monday, 15 July 2024
09:03	5 Top ETFs of Last Week	zacks.com
Friday, 12 July 2024
11:02	Inflation Cools in June, Triggers Spike in Laggard ETFs	zacks.com
Monday, 20 May 2024
18:00	5 Money Mistakes Billionaire Elon Musk Made	https://www.benzinga.com
16:00	Canada’s ‘Crypto King’ Facing Multiple Years Behind Bars for Allegedly Running $30,475,000 Fraud: Report	https://dailyhodl.com
12:18	SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp. - EVLV;EVLVW	https://feeds.newsfilecorp.com
03:19	SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp. - EVLV;EVLVW	https://feeds.newsfilecorp.com
Sunday, 19 May 2024
22:43	'Universal Basic Income Was A Good Idea': AI 'Godfather' Geoffrey Hinton Warns Of Job Losses And Extinction-Level Threat From Tech	http://feeds.benzinga.com
Tuesday, 5 March 2024
09:46	5 Best ETF Areas of Last Week	Zacks Investment Research
Monday, 4 March 2024
09:01	Top & Flop ETF Areas of Wall Street's Best February in Decade	Zacks Investment Research
Monday, 11 December 2023
14:17	Best-Performing ETFs of Last Week	Zacks Investment Research
Monday, 25 September 2023
14:17	Top and Flop Industry ETFs of Q3	Zacks Investment Research
Monday, 8 May 2023
09:08	4 Best-Performing ETF Areas of Last Week	Zacks Investment Research
Monday, 24 April 2023
17:48	ALPS' Biotech ETF SBIO Week's Top Performer	ETF Trends
14:28	Best ETF Areas of Last Week	Zacks Investment Research
Tuesday, 14 March 2023
09:11	3 ETF Areas Likely to be in Tight Spots Post Banking Crisis	Zacks Investment Research
Wednesday, 11 January 2023
18:09	Can Health Care Stocks Outperform Again In 2023?	Seeking Alpha
Monday, 3 October 2022
14:17	What Slump? 4 Sector ETFs Up At Least 14% in Q3	Zacks Investment Research
09:02	4 Best ETF Areas of Last Week That Are Up At Least 5%	Zacks Investment Research
Tuesday, 27 September 2022
09:02	5 Best Areas of Q3 of 2022 & Their Top ETFs	Zacks Investment Research
Friday, 26 August 2022
01:24	What The Inflation Reduction Act Means For Drug Prices	Seeking Alpha
Monday, 1 August 2022
09:16	Stocks' Best Month Since 2020: Top ETF Areas of July	Zacks Investment Research
Thursday, 28 July 2022
09:23	3 ETFs Braving Inflationary Fears in Past Three Months	Zacks Investment Research
Friday, 8 July 2022
12:25	5 ETFs Riding High on the Biotech Comeback	Zacks Investment Research
09:20	Pharma & Biotech ETFs at One-Month High: Here's Why	Zacks Investment Research
Tuesday, 5 July 2022
21:16	Biotech ETFs Are Making a Comeback	ETF Trends
Thursday, 30 June 2022
14:52	Biotech ETF Tops in June: 5 Stocks That Outperform	Zacks Investment Research
Wednesday, 29 June 2022
11:36	4 Sector ETFs That Survived Market Turmoil in June	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 14 Jan 2024

Week In Review: China Biopharmas Book $9B In Deals During JP Morgan Conference Week
Seeking Alpha 12 Jan 2024

Horiba: Wonderful Japanese Company At A Very Attractive Price
Seeking Alpha 7 Jan 2024

Week In Review: 2024 Kicks Off With 3 Deals Worth A Total Of $4B
Seeking Alpha 23 Jul 2023

Week In Review: Novartis In $1 Billion Deal For DTx Pharma
Seeking Alpha 24 Aug 2022

CytoDyn: It Only Takes One Hit
Seeking Alpha 24 Aug 2022

Coherus: 2022 Is In Many Ways A Make Or Break Year
Seeking Alpha 23 Aug 2022

Can Intellia One-Up Alnylam In Transthyretin Amyloidosis?
Seeking Alpha 17 Aug 2022

Atara: 2 Possible Regulatory Approvals For Tab-Cel, Plus CAR T Pipeline
Seeking Alpha 15 Aug 2022

Selecta: ImmTOR Could Change Autoimmune Disorder Treatment Landscape
Seeking Alpha 1 Aug 2022

SIGA Technologies: Unjustified Selloff, Loading The Boat, Best Monkeypox Play

Frequently Asked Questions (FAQ)

What's the price of Virtus LifeSci Biotech Clinical Trials ETF stock today?

One share of Virtus LifeSci Biotech Clinical Trials ETF stock can currently be purchased for approximately $22.51.
When is Virtus LifeSci Biotech Clinical Trials ETF's next earnings date?

Unfortunately, Virtus LifeSci Biotech Clinical Trials ETF's (BBC) next earnings date is currently unknown.
Does Virtus LifeSci Biotech Clinical Trials ETF pay dividends?

No, Virtus LifeSci Biotech Clinical Trials ETF does not pay dividends.
How much money does Virtus LifeSci Biotech Clinical Trials ETF make?

Virtus LifeSci Biotech Clinical Trials ETF has a market capitalization of 10.92M.
What is Virtus LifeSci Biotech Clinical Trials ETF's stock symbol?

Virtus LifeSci Biotech Clinical Trials ETF is traded on the AMEX under the ticker symbol "BBC".
What is Virtus LifeSci Biotech Clinical Trials ETF's primary industry?

Company operates in the Financial Services sector and Asset Management industry.
How do i buy shares of Virtus LifeSci Biotech Clinical Trials ETF?

Shares of Virtus LifeSci Biotech Clinical Trials ETF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
When Virtus LifeSci Biotech Clinical Trials ETF went public?

Virtus LifeSci Biotech Clinical Trials ETF is publicly traded company for more then 10 years since IPO on 17 Dec 2014.

Virtus LifeSci Biotech Clinical Trials ETF

Exchange:

AMEX

Full time employees:

Industry:

Asset Management

Sector:

Financial Services

Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

CIK: 0001559109
ISIN: US26923G3011
CUSIP: 26923G301